VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma

Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly comments on how BCMA targeting bispecific antibodies may impact the subsequent use of BCMA targeting CAR-T therapy in patients with multiple myeloma. Dr Krishnan also highlights the promising response rates observed with the use of bispecifics, and the importance of monitoring risk of infection in heavily pre-treated patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter